{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:45:20Z","timestamp":1789731920150,"version":"4.0.1"},"reference-count":33,"publisher":"Sociedad Espanola de Patologia Digestiva (SEPD)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Enferm Dig"],"published-print":{"date-parts":[[2017]]},"DOI":"10.17235\/reed.2017.5078\/2017","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T12:08:07Z","timestamp":1500984487000},"source":"Crossref","is-referenced-by-count":1,"title":["Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective"],"prefix":"10.17235","author":[{"given":"Isabel","family":"Vera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"J\u00fadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6910","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.029"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1182982"},{"key":"ref3","unstructured":"3.\tActavis. Actavis receives FDA approval for VIBERZI (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. 2015 May 27. http:\/\/www.actavis.com"},{"key":"ref4","unstructured":"4.\tU.S. Food and Drug Administration. FDA approves two therapies to treat IBS_D (2015 May 27)\t. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm448328.htm"},{"key":"ref5","unstructured":"5.\tTruberzi. Initial Public Assessment Report. (EMA\/549473\/2016) 2016 Jul 21 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004098\/WC500213370.pdf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505180"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/00365520152584770"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082011001100003"},{"key":"ref9","unstructured":"9.\tMearin F. Irritable bowel syndrome (IBS) subtypes: nothing resembles less an IBS than another IBS. Rev Esp Enferm Dig. 2016;108(2):57-8."},{"key":"ref10","unstructured":"10.\tMira JJ, Guilabert M, Sempere L, et al. The irritable bowel syndrome care process form the patients and professionals views. Rev Esp Enferm Dig 2015;107:202-210."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.03.008"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13746"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v6.i4.120"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302093"},{"key":"ref16","unstructured":"16.\tLembo A, Pimentel M, Raso SS, et al. Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET 3 study. Paper presented at the 2014 Annual Scientific Meeting of the American College of Gastroenterology; 2014 Oct 17-22; Philadelphia PA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2016.1140571"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.2710"},{"key":"ref19","unstructured":"19.\tHanauer SB. The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord. 2008;8:15-20."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609006766"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.122"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.223"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S32721"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.005"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-3150.2004.00554.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02068.x"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.09.015"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.04.006"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12716"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.01.026. [Epub ahead of print]"},{"key":"ref31","unstructured":"31.\tTruberzi. Eluxadoline. EPAR Summary for the public. EMA\/CHMP\/517539\/2016 (EMEA\/H\/C\/004098). Sep. 2016.\t http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=\/pages\/medicines\/human\/medicines\/004098\/human_med_002025.jsp&mid=WC0b01ac058001d124"},{"key":"ref32","unstructured":"32.\tProduct information: Truberzi. EMEA\/H\/C\/004098 -IB\/0002\/G (First published: 29 sep 2016; Last updated: 15 mar 2017).\t http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=\/pages\/medicines\/human\/medicines\/004098\/human_med_002025.jsp&mid=WC0b01ac058001d124"},{"key":"ref33","unstructured":"33. Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder. FDA. 2017 Mar 15.\t https:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm546771.htm"}],"container-title":["Revista Espa\u00f1ola de Enfermedades Digestivas"],"original-title":[],"deposited":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T12:08:08Z","timestamp":1500984488000},"score":1,"resource":{"primary":{"URL":"https:\/\/online.reed.es\/fichaArticulo.aspx?iarf=684760744235-414273198162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":33,"URL":"https:\/\/doi.org\/10.17235\/reed.2017.5078\/2017","relation":{},"ISSN":["1130-0108"],"issn-type":[{"value":"1130-0108","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}